Lighthouse Pharmaceuticals Announces Progression of LHP588 Clinical Development Program in Alzheimer’s Disease

- Pre-IND meeting related to Phase 2b SPRING trial completed with US FDA - World-class clinical advisory board to support clinical development plans SAN FRANCISCO, May 10, 2023 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to...

Click to view original post